Find Paper, Faster
Example:10.1021/acsami.1c06204 or Chem. Rev., 2007, 107, 2411-2502
Hypoxia-activated KDAC inhibitor: Taking a breath from untargeted therapy
Cell Chemical Biology  (IF8.116),  Pub Date : 2021-09-16, DOI: 10.1016/j.chembiol.2021.08.016
Maximilian Staudt, Manfred Jung

Use of hypoxia-activated prodrugs has emerged as a strategy for selectively targeting tumors in hypoxic conditions harboring reductive environments. In this issue of Cell Chemical Biology, Skwarska et al. (2021) report a hypoxia-activated prodrug targeting histone deacetylases (lysine deacetylases, KDACs) selectively over normoxic cells with activity in an animal model.